ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#683864, IND#61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma.

Protocol: 
AAAL5208
Phase: 
II

ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#683864, IND#61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma.

This randomized phase II trial studies how well irinotecan and temozolomide
works with dinutuximab in treating patients with relapsed/refractory
(returned/does not respond to treatment) neuroblastoma. Dinutuximab works by
attaching to neuroblastoma cells and stimulating the body’s immune system to
attack and kill the neuroblastoma cells. Irinotecan and temozolomide are
standard chemotherapy medicines that kill tumor cells. It is not yet known
whether giving irinotecan and temozolomide together with dinutuximab is more
effective in treating relapsed/refractory neuroblastoma.

Are you Eligible? (Inclusion Criteria)

-Subjects may be any age at the time of enrollment.
-Patients must have been diagnosed with neuroblastoma.
-Patients must have disease that is progressive, relapsed, or is refractory
to prior therapy.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States